In vitro inhibitory effects of phellodendrine on human liver cytochrome P450 enzymes

References

• Hao X, Yuan J, Xu Y, et al. (2017). In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica 48:1185–91.
   Web of Science ®Google Scholar
• Hattori T, Furuta K, Hayashi K, et al. (1992). Studies on the antinephritic effects of plant components (6): antinephritic effects and mechanisms of phellodendrine (OB-5) on crescentic-type anti-GBM nephritis in rats (2). Jpn J Pharmacol 60:187–95.
   PubMedGoogle Scholar
• Hu X, Huang W, Yang Y. (2015). Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet 40:373–7.
   PubMed Web of Science ®Google Scholar
• Jeong HU, Kong TY, Kwon SS, et al. (2013). Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 18:10681–93.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, et al. (2016). Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica 47:16.
   Google Scholar
• Li AP. (2001). Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 6:357–66.
   PubMed Web of Science ®Google Scholar
• Li L, Huang T, Tian C, et al. (2016a). The defensive effect of phellodendrine against AAPH-induced oxidative stress through regulating the AKT/NF-kappaB pathway in zebrafish embryos. Life Sci 157:97–106.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu XG, Wang HY, et al. (2016b). Pharmacokinetic studies of phellodendrine in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1029–1030:95–101.
   PubMed Web of Science ®Google Scholar
• Lim YP, Chen WC, Cheng CH, et al. (2014). Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med 80:1097–106.
   PubMed Web of Science ®Google Scholar
• Liu T, Qian G, Wang W, Zhang Y. (2015). Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet 40:235–8.
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu K. (2014). Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab 15:791–807.
   PubMed Web of Science ®Google Scholar
• Mori H, Fuchigami M, Inoue N, et al. (1994). Principle of the bark of Phellodendron amurense to suppress the cellular immune response. Planta Med 60:445–9.
   PubMed Web of Science ®Google Scholar
• Mori H, Fuchigami M, Inoue N, et al. (1995). Principle of the bark of Phellodendron amurense to suppress the cellular immune response: effect of phellodendrine on cellular and humoral immune responses. Planta Med 61:45–9.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35:246–55.
   PubMed Web of Science ®Google Scholar
• Pandit S, Mukherjee PK, Ponnusankar S, et al. (2011). Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia 82:369–74.
   PubMed Web of Science ®Google Scholar
• Peyrat-Maillard MN, Cuvelier ME, Berset C. (2003). Antioxidant activity of phenolic compounds in 2,2′-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced oxidation: synergistic and antagonistic effects. J Am Oil Chem 10:1007–12.
   Web of Science ®Google Scholar
• Pirotta M, Willis K, Carter M, et al. (2014). 'Less like a drug than a drug': the use of St John's wort among people who self-identify as having depression and/or anxiety symptoms. Complement Ther Med 22:870–6.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, et al. (2013). Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 56:392–7.
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, et al. (1997). Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401–8.
   PubMed Web of Science ®Google Scholar
• Singh AP, Pant MC, Ruwali M, et al. (2010). Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark 8:351–9.
   PubMed Web of Science ®Google Scholar
• Thu PM, Zheng ZG, Zhou YP, et al. (2019). Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis. Eur J Pharmacol 850:23–34.
   PubMed Web of Science ®Google Scholar
• Unger M. (2013). Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev 45:353–85.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Liu F, et al. (2017). The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. Pharm Biol 55:1863–7.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou SF. (2009). Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 16:4066–218.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1–21.
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. (2001). Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 1:403–25.
   PubMedGoogle Scholar
• Ye X, Li W, Yan Y, et al. (2010). Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 192:212–20.
   PubMed Web of Science ®Google Scholar
• Ye L, Yang X, Guo E, et al. (2014). Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One 9:e96664
   PubMed Web of Science ®Google Scholar
• Zhang QH, Hu JP, Wang BL, Li Y. (2012). Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res 14:382–95.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, et al. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496–503.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ya G, Rui H. (2016). Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet 42:89–98.
   Web of Science ®Google Scholar
• Zhang J, Li C, Zhang F. (2018). In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes. Xenobiotica 1–14.
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu S, Wang Y, et al. (2015). Effects of Curculigoside on Memory Impairment and Bone Loss via Anti-Oxidative Character in APP/PS1 Mutated Transgenic Mice. PLoS One 10:e0133289.
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–22.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li SC, et al. (2004). Predicting pharmacokinetic herb–drug interactions. Drug Metabol Drug Interact 20:143–58.
   PubMedGoogle Scholar
• Zimmerlin A, Trunzer M, Faller B. (2011). CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos 39:1039–46.
   PubMed Web of Science ®Google Scholar